<p>, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在調查 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）投資者可能違反聯邦證券法的情況。</p>
<p>2025 年 11 月 3 日，uniQure 發佈了一份新聞稿，透露 FDA 通知公司，其針對亨廷頓舞蹈症的研究性基因療法 AMT-130 的數據未能提供足夠的證據來支持 uniQure 的生物製品許可申請（&#34;BLA&#34;）提交。具體而言，uniQure 披露公司認為 FDA 目前不再同意 AMT-130 的 I/II 期研究數據可能足以作為 BLA 提交的主要證據，並且由於這一原因，AMT-130 的 BLA 提交時間現在變得不明確。</p>
<p>在這一消息發佈後，uniQure 的股價下跌超過 50%，從 2025 年 10 月 31 日的收盤價 67.69 美元跌至 2025 年 11 月 3 日的收盤價 34.29 美元。</p>
<p><strong><em>如果您是 uniQure 的投資者並希望瞭解更多關於我們調查的信息，請點擊此處填寫我們的在線表格或聯繫 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或發送電子郵件至 [email protected].</em></strong> <strong><em>您也可以點擊以下鏈接或將其粘貼到您的瀏覽器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<p>Kessler Topaz Meltzer &amp; Check, LLP 在全國各州和聯邦法院起訴涉及證券欺詐、違反信託責任和其他州及聯邦法律的集體訴訟。Kessler Topaz Meltzer &amp; Check, LLP 是公司治理改革的推動力量，已為來自美國及全球的機構和個人投資者追回數十億美元。該事務所代表投資者、消費者和舉報人（向政府報告欺詐行為的私人公民，並分享政府資金的追回）。有關 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，請訪問 www.ktmc.com。</p>
<p>聯繫方式：</p>
<p>Kessler Topaz Meltzer &amp; Check, LLP</p>
<p>Jonathan Naji, Esq.</p>
<p>280 King of Prussia Road</p>
<p>Radnor, PA 19087</p>
<p>(484) 270-1453</p>
<p>[email protected]</p>
<p>在某些司法管轄區可能被視為律師廣告。過去的結果並不保證未來的結果。</p>
<p>來源 Kessler Topaz Meltzer &amp; Check, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0"/></p>

QURE

<p>Kessler Topaz Meltzer & Check, LLP 正在調查 uniQure N.V.（NASDAQ: QURE）可能違反聯邦證券法的情況，此前 FDA 表示其 AMT-130 基因療法的數據不足以支持生物製品許可申請。這導致 uniQure 的股價下跌了 50%。遭受重大損失的投資者被鼓勵與該公司聯繫以獲取更多信息</p>

<p>, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (&#34;uniQure&#34;).</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在調查 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）投資者可能違反聯邦證券法的情況。</p>
</div><p>On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application (&#34;BLA&#34;) submission. Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.</p>
<div class="lb-trans"><p>2025 年 11 月 3 日，uniQure 發佈了一份新聞稿，透露 FDA 通知公司，其針對亨廷頓舞蹈症的研究性基因療法 AMT-130 的數據未能提供足夠的證據來支持 uniQure 的生物製品許可申請（&#34;BLA&#34;）提交。具體而言，uniQure 披露公司認為 FDA 目前不再同意 AMT-130 的 I/II 期研究數據可能足以作為 BLA 提交的主要證據，並且由於這一原因，AMT-130 的 BLA 提交時間現在變得不明確。</p>
</div><p>On this news, the price of uniQure's stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025.</p>
<div class="lb-trans"><p>在這一消息發佈後，uniQure 的股價下跌超過 50%，從 2025 年 10 月 31 日的收盤價 67.69 美元跌至 2025 年 11 月 3 日的收盤價 34.29 美元。</p>
</div><p><strong><em>If you are a uniQure investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer &amp; Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at [email protected].</em></strong> <strong><em>You can also click on the following link or paste it in your browser:</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<div class="lb-trans"><p><strong><em>如果您是 uniQure 的投資者並希望瞭解更多關於我們調查的信息，請點擊此處填寫我們的在線表格或聯繫 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或發送電子郵件至 [email protected].</em></strong> <strong><em>您也可以點擊以下鏈接或將其粘貼到您的瀏覽器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
</div><p>Kessler Topaz Meltzer &amp; Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer &amp; Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit www.ktmc.com.</p>
<div class="lb-trans"><p>Kessler Topaz Meltzer &amp; Check, LLP 在全國各州和聯邦法院起訴涉及證券欺詐、違反信託責任和其他州及聯邦法律的集體訴訟。Kessler Topaz Meltzer &amp; Check, LLP 是公司治理改革的推動力量，已為來自美國及全球的機構和個人投資者追回數十億美元。該事務所代表投資者、消費者和舉報人（向政府報告欺詐行為的私人公民，並分享政府資金的追回）。有關 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，請訪問 www.ktmc.com。</p>
</div><p>CONTACT:</p>
<div class="lb-trans"><p>聯繫方式：</p>
</div><p>Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p>Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p>Jonathan Naji, Esq.</p>
<div class="lb-trans"><p>Jonathan Naji, Esq.</p>
</div><p>280 King of Prussia Road</p>
<div class="lb-trans"><p>280 King of Prussia Road</p>
</div><p>Radnor, PA 19087</p>
<div class="lb-trans"><p>Radnor, PA 19087</p>
</div><p>(484) 270-1453</p>
<div class="lb-trans"><p>(484) 270-1453</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.</p>
<div class="lb-trans"><p>在某些司法管轄區可能被視為律師廣告。過去的結果並不保證未來的結果。</p>
</div><p>SOURCE Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p>來源 Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC31164&amp;Transmission_Id=202511221140PR_NEWS_USPR_____DC31164&amp;DateId=20251122"/></p>

11:40 ET
			
			
				QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

QURE 調查通知：Kessler Topaz Meltzer & Check, LLP 鼓勵在 Uniqure N.V. (NASDAQ: QURE) 上遭受重大損失的投資者與該公司聯繫